today
We have developed a new class of peptide- mimicking drugs to enhance the activity of an endogenous neurotrophic factor called BDNF (Brain-Derived Neurotrophic Factor). Increasing BDNF activity has shown therapeutic benefits for not only depression, but an array of brain disorders.
At Aingeal, our focus is on developing therapeutics for Treatment-Resistant Depression, Angelman Syndrome, and Traumatic Brain Injury.